Expert Interview
A Second View: Discussing the current treatment landscape for tuberculosis and new therapies in development including GSK3036656 in development from GSK in light of the recent positive results from a Phase IIa study.
Ticker(s): GSKInstitution: Christus Health
- Infectious Disease specialist and Internal medicine specialist at Christus Health
- Manages 5 patients with tuberculosis
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
